IceCure highlights 5-year ICE3 breast cancer trial showing 3.1% recurrence rate after cryoablation
ICCM•Ongoing study reference
The review also referenced ongoing work, including IceCure’s ChoICE post-marketing trial, with future results expected from that study.
ICE3 trial results support cryoablation in selected patients
IceCure highlighted two new peer-reviewed publications supporting cryoablation as a less invasive option in breast cancer care.
Results from the ICE3 clinical study were already presented, with outcomes described as encouraging for selected early-stage, low-risk patients.
Publication expands discussion to axillary lymph node metastases
A separate publication broadened the clinical discussion to cryoablation for axillary lymph node metastases in curative or palliative settings.
